Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Sari, Youssef ^a,b   Prieto, Anne L ^a   Barton, Scott J ^a   Miller, Benjamin R ^a,c   Rebec, George V ^a  

^a INDIANA UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; SODIUM CHLORIDE; VESICULAR GLUTAMATE TRANSPORTER 1; ANTIINFECTIVE AGENT; EXCITATORY AMINO ACID TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; METABOLISM; TRANSGENIC MOUSE;

MUS;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; BLOTTING, WESTERN; CEFTRIAXONE; EXCITATORY AMINO ACID TRANSPORTER 2; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; UP-REGULATION;

EID: 77954881329     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-62     Document Type: Article

References (26)

1. Excitotoxic injury of the neostriatum: a model for Huntington's disease. M DiFiglia, Trends Neurosci 1990 13 7 286 289 10.1016/0166-2236(90)90111-M 1695405
2. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. F Fonnum J Storm-Mathisen I Divac, Neuroscience 1981 6 5 863 873 10.1016/0306-4522(81)90168-8 6113562
3. Huntington's Disease. PS Harper, W.B. Saunders London 2 1996
4. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. CA Ross, Neuron 2002 35 5 819 822 10.1016/S0896-6273(02)00872-3 12372277
5. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. PF Behrens P Franz B Woodman KS Lindenberg GB Landwehrmeyer, Brain 2002 125 Pt 8 1908 1922 10.1093/brain/awf180 12135980
6. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. JC Lievens B Woodman A Mahal O Spasic-Boscovic D Samuel L Goff Kerkerian-Le GP Bates, Neurobiol Dis 2001 8 5 807 821 10.1006/nbdi.2001.0430 11592850
7. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. BR Miller JL Dorner M Shou Y Sari SJ Barton DR Sengelaub RT Kennedy GV Rebec, Neuroscience 2008 153 1 329 337 10.1016/j.neuroscience.2008.02.004 18353560
8. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. B Hassel S Tessler RL Faull PC Emson, Neurochem Res 2008 33 2 232 237 10.1007/s11064-007-9463-1 17726644
9. Glutamate uptake. NC Danbolt, Prog Neurobiol 2001 65 1 1 105 10.1016/S0301-0082(00)00067-8 11369436
10. The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype. MB Robinson, Neurochem Int 1998 33 6 479 491 10.1016/S0197-0186(98)00055-2 10098717
11. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. AM Estrada-Sanchez T Montiel J Segovia L Massieu, Neurobiol Dis 2009 34 1 78 86 10.1016/j.nbd.2008.12.017 19168136
12. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. JD Rothstein S Patel MR Regan C Haenggeli YH Huang DE Bergles L Jin M Hoberg Dykes S Vidensky DS Chung SV Toan LI Bruijn ZZ Su P Gupta PB Fisher, Nature 2005 433 7021 73 77 10.1038/nature03180 15635412
13. The corticostriatal pathway in Huntington's disease. C Cepeda N Wu VM Andre DM Cummings MS Levine, Prog Neurobiol 2007 81 5-6 253 271 10.1016/j.pneurobio.2006.11.001 17169479
14. Altered information processing in the prefrontal cortex of Huntington's disease mouse models. AG Walker BR Miller JN Fritsch SJ Barton GV Rebec, J Neurosci 2008 28 36 8973 8982 10.1523/JNEUROSCI.2804-08.2008 18768691
15. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. L Mangiarini K Sathasivam M Seller B Cozens A Harper C Hetherington M Lawton Y Trottier H Lehrach SW Davies GP Bates, Cell 1996 87 3 493 506 10.1016/S0092-8674(00)81369-0 8898202
16. Upregulation of GLT1 attenuates cue-induced reinstatement of cocaine-seeking behavior in rats. Y Sari KD Smith PK Ali GV Rebec, J Neurosci 2009 29 29 9239 9243 10.1523/JNEUROSCI.1746-09.2009 19625514
17. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. RJ Carter LA Lione T Humby L Mangiarini A Mahal GP Bates SB Dunnett AJ Morton, J Neurosci 1999 19 8 3248 3257 10191337 (Pubitemid 29174016)
18. Nuclear factor-kappaB in cancer development and progression. M Karin, Nature 2006 441 7092 431 436 10.1038/nature04870 16724054
19. Mechanism of ceftriaxone induction of excitatory amino Acid transporter-2 expression and glutamate uptake in primary human astrocytes. SG Lee ZZ Su L Emdad P Gupta D Sarkar A Borjabad DJ Volsky PB Fisher, J Biol Chem 2008 283 19 13116 13123 10.1074/jbc.M707697200 18326497
20. Modulation of neuronal protein trafficking and function by palmitoylation. K Huang A El-Husseini, Curr Opin Neurobiol 2005 15 5 527 535 10.1016/j.conb.2005.08.001 16125924
21. Palmitoylation and function of Glial Glutamate Transporter-1 is reduced in the YAC128 mouse model of Huntington disease. K Huang MH Kang C Askew R Kang SS Sanders J Wan NG Davis MR Hayden, Neurobiology of Disease
22. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - an in situ hybridization study. T Arzberger K Krampfl S Leimgruber A Weindl, J Neuropathol Exp Neurol 1997 56 4 440 454 10.1097/00005072-199704000-00013 9100675
23. Selective up-regulation of the glial Na+dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. R Ganel T Ho NJ Maragakis M Jackson JP Steiner JD Rothstein, Neurobiol Dis 2006 21 3 556 567 10.1016/j.nbd.2005.08.014 16274998
24. Glutamate transporters in neurologic disease. NJ Maragakis JD Rothstein, Arch Neurol 2001 58 3 365 370 10.1001/archneur.58.3.365 11255439
25. Neuroprotective agents for clinical trials in ALS: a systematic assessment. BJ Traynor L Bruijn R Conwit F Beal G O'Neill SC Fagan ME Cudkowicz, Neurology 2006 67 1 20 27 10.1212/01.wnl.0000223353.34006.54 16832072
26. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. R Nau HW Prange P Muth G Mahr S Menck H Kolenda F Sorgel, Antimicrob Agents Chemother 1993 37 7 1518 1524 8363385